Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

Shukui Qin,1 Feng Bi,2 Jie Jin,3 Ying Cheng,4 Jun Guo,5 Xiubao Ren,6 Yiran Huang,7 Jamal Tarazi,8 Jie Tang,9 Connie Chen,9 Sinil Kim,8 Dingwei Ye10 1Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, People’s Republic of China; 2Department of Medic...

Full description

Bibliographic Details
Main Authors:	Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-06-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/axitinib-versus-sorafenib-as-a-second-line-therapy-in-asian-patients-w-peer-reviewed-article-OTT

Similar Items

Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
by: Wang H, et al.
Published: (2016-06-01)

Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study
by: Huang, J., et al.
Published: (2022)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
by: Karakiewicz PI, et al.
Published: (2016-05-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
by: Shen Yijun, et al.
Published: (2009-07-01)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
by: Masashi Kimura, et al.
Published: (2019-01-01)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
by: Wen Cai, et al.
Published: (2019-10-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
by: Billy Amzal, et al.
Published: (2017-01-01)

Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
by: Manan Shah, et al.
Published: (2020-04-01)

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma
by: Jindrich Kopecky, et al.
Published: (2018-11-01)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
by: Ansari J, et al.
Published: (2013-02-01)

Axitinib in the successive targeted therapy of patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2014-11-01)

Axitinib in the successive targeted therapy of patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2014-11-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
by: Lin Yang, et al.
Published: (2018-02-01)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017-09-01)

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian “Real-Word” SAX study
by: Carmine D'Aniello, et al.
Published: (2016-09-01)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
by: Gaetano Facchini, et al.
Published: (2019-08-01)

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
by: Ana Elena Martín-Aguilar, et al.
Published: (2021-01-01)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
by: Alison C. Johnson, et al.
Published: (2017-05-01)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
by: Gr&uuml;enwald V, et al.
Published: (2012-06-01)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
by: Verzoni E, et al.
Published: (2014-03-01)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
by: Narayan V, et al.
Published: (2016-03-01)

Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
by: T. Anders Olsen, et al.
Published: (2021-02-01)

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study
by: Yoshifumi Kadono, et al.
Published: (2019-09-01)

Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?
by: R. A. Gafanov, et al.
Published: (2020-11-01)

Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
by: Panagiotis Vlachostergios
Published: (2020-06-01)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
by: Gunnarsson O, et al.
Published: (2015-02-01)

Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma
by: Ryo Kasahara, et al.
Published: (2017-01-01)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
by: Peiyao Lu, et al.
Published: (2020-05-01)

Stabilization of metastatic myxopapillary ependymoma with sorafenib
by: Christine Marosi, et al.
Published: (2012-06-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy
by: Ichiro Yonese, et al.
Published: (2020-07-01)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
by: Caroline Randrup Hansen, et al.
Published: (2017-02-01)